Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating the safety and efficacy of CAR-T products are ongoing, and many experts in the field are eager to see how the availability of CAR-T products will influence the treatment landscape. Of course, access to novel therapies varies in different regions, and while there are many approvals going through NICE, there are still questions that remain regarding lymphoma treatment in the UK.

In this exclusive podcast, Robin Sanderson, BSc, MBChB, MRCP, FRCPath, PhD, of King's College Hospital NHS Foundation Trust, London, UK, and Tobias Menne, MD, PhD, FRCPath, of the Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK, discuss lymphoma treatment in the UK, drawing focus on CAR-T therapy, including the management toxicities, treating transplant-ineligible patients, and more.